on September 18, 2003
Published online before print September 18, 2003, doi: 10.1161/01.ATV.0000078522.50981.55
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 28, 2003
Accepted on May 12, 2003
Nitric Oxide Synthase Gene Transfer as a Tool to Study Biology of Endothelial Cells
Zvonimir S. Katusic *;
From the Department of Anesthesiology and Molecular Pharmacology and Experimental Therapeutics (Z.S.K.); Department of Medicine, Division of Cardiovascular Diseases (N.M.C.); Division of Nephrology (K.A.N.); and Molecular Medicine Program (Z.S.K., K.A.N.), Mayo Clinic, Rochester, Minn.
* To whom correspondence should be addressed. E-mail: katusic.zvonimir{at}mayo.edu.
Abstract--During the past decade, the development of gene transfer technology provided a powerful and facile tool that afforded the genetic modification of vascular endothelial function. This development has coincided with molecular cloning and extensive accumulation of knowledge concerning the role of nitric oxide synthase isoforms in vascular homeostasis. Experimental evidence continues to accumulate that in vivo adenovirus-mediated gene transfer into the vessel wall is a very useful technique in studies designed to characterize function of a given gene or protein. In this review, we will use nitric oxide synthase gene transfer as a paradigm to illustrate how gene transfer technology can be used to address key issues in the vascular biology of endothelium.
Key words: adenovirus • endothelium • superoxide Anion • protein kinase Akt • vascular endothelial growth factor
This article has been cited by other articles:
 |
|
 |
|
  M. P. Coggins and K. D. Bloch Nitric Oxide in the Pulmonary Vasculature Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1877 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-H. Chen and D. L. Wang Nitric Oxide Inhibits Matrix Metalloproteinase-2 Expression via the Induction of Activating Transcription Factor 3 in Endothelial Cells Mol. Pharmacol., May 1, 2004; 65(5): 1130 - 1140. [Abstract] [Full Text]
|
|